A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Alemtuzumab (Primary) ; Aciclovir; Cetirizine; Dexchlorpheniramine; Diphenhydramine; Glatiramer acetate; Histamine H1 receptor antagonists; Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Interferon beta; Interferon beta; Methylprednisolone; Paracetamol; Prednisolone; Ranitidine
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms LemKids
- Sponsors Sanofi Genzyme
Most Recent Events
- 01 Jan 2025 Results evaluating the efficacy, safety, and tolerability of alemtuzumab in pediatric patients with relapsing-remitting multiple sclerosis (RRMS) and disease activity on prior disease-modifying therapies published in the Multiple Sclerosis Journal.
- 10 Jan 2024 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 19 Dec 2022 This trial has been Discontinued in Italy, according to European Clinical Trials Database record